Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saliva test to predict premature births:

This article was originally published in Clinica

Executive Summary

Biex's SalEst saliva test has obtained FDA marketing approval for use in predicting premature birth in third-trimester women. SalEst measures the level of the hormone estriol, which appears in saliva a few weeks before spontaneous pre-term labour occurs. The test, which will be available later this year, identifies the "vast majority" of affected women, says Dublin, California-based Biex, compared with the less than 50% accuracy of traditional risk scoring systems. It will be the company's first product.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel